Sanofi invests €300m in Orano Meds lead-based radioligands
Summary
Sanofi is investing €300 million in Orano Med to expand its radioligand therapy business for cancer. The deal strengthens Sanofi’s partnership with Orano Med and RadioMedix around AlphaMedix, a lead-212-based therapy for rare neuroendocrine tumours. Orano Med is also building what it says will be Europe’s first industrial-scale facility for producing lead-212 radiotherapies. The investment reflects growing interest in radiopharmaceuticals and the supply advantages of lead-212 over other alpha emitters. This move could accelerate development, manufacturing, and regulatory work across the partnership.
Funding
Amount
$325.0M
Total raised
Date
October 10, 2025
Announcement date
Investors
Amylin Pharmaceuticals, U.S. Food and Drug Administration, Bayer, Novartis Venture Fund, Aventis, Bristol-Myers Squibb Foundation
Lead investors
Company
orano.group
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected